CG InvitesCG인바이츠

CG Invites is loss-making at the operating level, though it reported a small net profit over the trailing twelve months to H1 2026.

The Korean biotech and pharma company, listed on KOSDAQ, had trailing revenue of about ₩27.0B to H1 2026 but an operating loss of about ₩22.7B, an operating margin of -83.8%. Its shares closed at ₩1,000 on 28 October 2026, down 38.4% over one year and well below their 52-week high of ₩1,667. The company profile in the data does not describe its products, customers or markets, so the business itself cannot be assessed from this pack.

What stands out

• Trailing net income of ₩0.4B is positive, but operating income of -₩22.7B and free cash flow of -₩4.6B show the core business is not covering its costs.
• Revenue jumped 277.6% in 2025 to ₩27.4B after falling in 2023, but operating losses have been large in every year from 2021 to 2025.
• Cash of ₩5.9B against borrowings of ₩6.4B, with liabilities at 108.9% of equity, leaves a thin balance sheet.
• Valuation metrics are mixed: P/E of 179.3 on trailing earnings, P/B of 0.8 and P/S of 2.8; the dividend yield is 0%.
• Recent filings include a 5%+ holding report, an acquisition of shares in another company (later amended), and a shareholders' meeting, but no news headlines were provided to explain them.

What to watch

• The next half-year or annual results, to see whether operating losses narrow relative to revenue.
• Details of the share acquisition and the amended major sales or supply contract filings, which the data does not explain.
• Funding needs given negative free cash flow and borrowings above cash; the data does not state any going-concern assessment.